Trending Now
We have updated our Privacy Policy and Terms of Use for Eurasia Group and its affiliates, including GZERO Media, to clarify the types of data we collect, how we collect it, how we use data and with whom we share data. By using our website you consent to our Terms and Conditions and Privacy Policy, including the transfer of your personal data to the United States from your country of residence, and our use of cookies described in our Cookie Policy.
{{ subpage.title }}
What We’re Watching: US vaccine patent U-turn, right wins big in Madrid, Biden weighs in on Russia-Ukraine
US reverses course on vaccine patents: In a surprise move, the Biden administration will now support waiving international property rights for COVID vaccines at the World Trade Organization. Until now the US had firmly opposed waiving those patents, despite demands from developing countries led by India and South Africa to do so. Biden's about face comes just a week after he moved to free up 60 million of American-bought AstraZeneca jabs — still not approved by US regulators — for nations in need. It's not clear how fast an IP waiver would really help other countries, as the major impediments to ramping up vaccine manufacturing have more to do with logistics and supply chains than with patent protections alone. But if patent waivers do accelerate production over time, then that could accelerate a globalreturn to normal — potentially winning the US a ton of goodwill.
The left gets pummeled in Madrid: The two leftwing parties in Spain's national government got massacred in regional elections in Madrid this week. Both the center-left PSOE and the far-left Podemos were steamrolled by the conservative Popular Party, which more than doubled its current seats to win 64, just four shy of a majority on its own in the Madrid legislature. The PP may now even turn to the upstart far-rightists of Vox in order to form a coalition government in Madrid. The defeat was a crushing blow for Prime Minister Pedro Sánchez of the PSOE, who has often clashed with Madrid's pugnacious regional leader over the latter's disdain for economy-crippling lockdowns. Moreover, the surge in support for PP and Vox in Madrid — always an influential bellwether for national politics — will make him very reluctant to call early elections, which he was considering doing because the PP until recently was in big trouble following its dismal showing in the Catalan election just three months ago. Interesting times ahead for Spanish politics.
Biden, Ukraine, and Russia: I'd like to speak face-to-face with Russian President Vladimir Putin sometime this summer, says US President Joe Biden. Not a bad idea, says the Kremlin. If it happens, the two leaders are sure to talk about Ukraine, and there have been suggestions this week that the US might join Germany and France in efforts to mediate the conflict and find a path to peace. US Secretary of State Tony Blinken is actually in Kyiv this week to assert "unwavering US support for Ukraine's sovereignty and territorial integrity in the face of Russia's ongoing aggression." Russia has lately been dialing up the pressure on Ukraine – with a brief military buildup along the border between the two countries, military exercises in the disputed Crimea peninsula, and Russian threats to blockade key Ukrainian ports. These are reminders that the central challenge for any mediator is ending a conflict that Russia's government still finds useful for both domestic and international purposes.Would you get rid of COVID-19 vaccine patents?
Vaccines are the best hope to end the COVID-19 pandemic. But rich countries are hogging most of the doses, with more than 83 percent of shots administered to date having gone to residents in high- and upper-middle-income countries. Most poor countries will have to wait years to achieve widespread vaccination, according to one study.
To address this inequity some stakeholders are pushing hard for waivers to intellectual-property (IP) rights through World Trade Organization trade rules so that manufacturers in poorer countries can make their own vaccines locally. India and South Africa have been leading the charge, which would essentially mean that deep-pocketed pharma companies like New York-based Pfizer, for instance, would have to hand over the keys to the kingdom, allowing local companies in New Delhi and Johannesberg to make generic versions of their vaccines.
Unsurprisingly, the debate has gotten fiery, with passionate arguments emerging both for and against.
What are some arguments for a waiver?
It's the humane thing to do. To date, only 0.2 percent of all COVID vaccine doses have been administered in low-income countries. The virus is still spreading like wildfire in many places, and hospitalization and deaths are soaring in countries like India and Brazil. Relaxing rules on patents would mean more people would get vaccinated more quickly, saving scores of lives. The cost-benefit analysis is simple, argue advocates of waivers to IP rights like US Senator Bernie Sanders.
The economics of it all. In order for the global economy to return to sustained growth, equitable access to vaccines is crucial. Patents only serve the specific commercial interests of big pharma companies (Pfizer is making a 25-30 percent profit off its vaccine sales, making it one of the most "lucrative drugs" in the world.) The global economic bounce-back is dependent on a speedy global vaccination drive, and relaxing IP rules will fuel a surge in production.
Empowering lower-income states. Without a waiver, poorer countries will remain at the mercy of the US, the UK and the EU, which is itself mired in a complicated vaccine fiasco. Dependency on the "charity" of wealthy countries — and their multi-billionaire pharma industries — that could take years to deliver, is not a sustainable solution as countries race to prevent the spread of new more contagious variants. (Consider that Africa currently imports 99 percent of its vaccines for a population of 1.3 billion.)
What are some arguments against a waiver?
It would discourage innovation. Waiving IP rules for COVID-19 vaccines will disincentivize big pharmaceutical companies from investing time and money in complicated research and development required to produce safe and effective drugs. Taking away such a massive incentive for innovation would stunt developments needed to address future pressing health crises.
Quality control. Unlike medications, which are basic compounds that can be easily reproduced by trained chemists, new age vaccines are complicated biologics that use basic ingredients (sugar, gelatin, proteins) as well as modified viruses (viral vectors) and genetic technology (mRNA). To safely and effectively copy a vaccine, manufacturers need to have access to and understand the formula, and need the originator's full assistance to get such a complex operation off the ground. Failure to ensure this by hastily lifting IP rights could result in millions of potentially unsafe doses at a time when vaccine hesitancy remains high in many countries. Amid recent negotiations with Pfizer, the Australian government said that setting up the required tech to safely produce Pfizer's (mRNA) vaccine locally would take at least one year.
Think outside the box. Removing IP protections is not the only — nor the best — way to address the problem. One vaccine specialist has suggested that companies should license their IP rights to third parties in a "technology transfer" arrangement, resulting in more companies manufacturing doses (this could also happen through rich countries investing in infrastructure). Ngozi Okonjo-Iweala, the new WTO chief who has lobbied against "vaccine nationalism," has pointed to the licensing deal between UK-based AstraZeneca and India's Serum Institute as a model. Partnerships are also happening in the US, where the Biden administration brokered a deal between Merck and Johnson & Johnson, rival pharmaceutical companies, to boost production.